| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.0083 | 0.9 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |